Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of glioma for…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key glioma patient populations covering 171 countries and more than 99% of…
For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving…
Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key NK/T-cell patient populations covering 171 countries and more than 99%…